Breaking News

BioFocus Achieves UCB Milestone

December 5, 2012

Discovery milestone triggers payment

BioFocus has achieved a development milestone under its medicinal chemistry services agreement with UCB for the discovery and development of next generation treatments for severe diseases. BioFocus has received an undisclosed milestone payment related to the candidate selection stage.
 
“This milestone payment from UCB demonstrates BioFocus’ ability to support its client projects through to success,” said Chris Newton, senior vice president, Galapagos Services.  “This innovative collaboration allows UCB to progress their program externally while applying the specific project expertise that UCB had already built internally.”
 
Neil Weir, senior vice president of discovery, UCB, and chair of the Innovation Board of the Association of the British Pharmaceutical Industry, said, “We are pleased with BioFocus’ contribution and our achievement in reaching this milestone.  Collaborations like this one with BioFocus are a foundation of UCB’s strategy and we believe advances towards new therapies can be accelerated by combining our expertise in discovery science with a wide network.”
  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars